<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Burr cells, acanthocytes, and target cells: Disorders of red blood cell membrane</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford M Takemoto, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert T Means, Jr, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Some red blood cell (RBC) disorders affect the shape of the cells by altering the plasma membrane composition or the ratio of plasma membrane to intracellular volume. Three of the most common morphologies are burr cells (echinocytes), acanthocytes, and target cells. This topic discusses their mechanisms of formation and their usefulness in identifying systemic disorders. </p><p>Separate topic reviews discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Assembly and regulation of the RBC membrane – (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of the submembrane cytoskeleton – (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis"</a> and  <a class="medical medical_review" href="/d/html/7087.html" rel="external">"Hereditary elliptocytosis and related disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of RBC hydration – (See  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"</a>.)</p><p></p><p class="headingAnchor" id="H1242682032"><span class="h1">TERMINOLOGY AND BEST PRACTICES FOR VIEWING</span><span class="headingEndMark"> — </span>Burr cells (echinocytes) and acanthocytes are two types of spiculated red blood cells (RBCs). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burr cells </strong>– Burr cells (echinocytes; from the prefix "echino" [spiny, prickly, sea urchin]) have a uniform array of relatively small spicules that appear as serrated edges distributed evenly across the entire surface of the cell, as shown in the images of a stained blood film  (<a class="graphic graphic_picture graphicRef121023" href="/d/graphic/121023.html" rel="external">picture 1</a>) and electron microscopy image  (<a class="graphic graphic_picture graphicRef130751" href="/d/graphic/130751.html" rel="external">picture 2</a>). </p><p></p><p class="bulletIndent1">The spicules in burr cells are more regular and numerous compared with acanthocytes. They are associated with disorders leading to intracellular adenosine triphosphate (ATP) depletion and can also commonly arise as an artifact from prolonged storage of RBCs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acanthocytes</strong> – Acanthocytes; from the Greek "acantha" (thorn) have only a few spicules of various sizes at irregular intervals on the cell surface and are denser than echinocytes  (<a class="graphic graphic_picture graphicRef120809" href="/d/graphic/120809.html" rel="external">picture 3</a>). Some experts consider "spur cell" to be synonymous with acanthocyte, while others consider spur cells to be an extreme form (a subset) of acanthocytes with a single spike or a few spikes, specific to liver disease with increased hemolysis and portending a very poor prognosis. (See <a class="local">'RBC changes in liver disease'</a> below.)</p><p></p><p class="bulletIndent1">When acanthocytes are remodeled by the spleen, the spicules become blunter and the associated membrane loss makes them more spherocytic; these cells may be referred to as spheroacanthocytes.</p><p></p><p>A freshly prepared peripheral blood smear is essential for distinguishing between these cell types, as storage may induce burr cell formation and other morphologic artifacts [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear", section on 'Slide preparation'</a>.)</p><p>A study of the effect of freshly prepared versus dried blood smears in 100 individuals with neuroacanthocytosis and 68 controls (some with other movement disorders and some without any medical diagnosis) found that use of blood that was isotonically diluted with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and viewed as an unfixed wet prep between two glass slides provided the best sensitivity (100 percent) and specificity (98 percent) for identifying acanthocytes [<a href="#rid2">2</a>]. Performance characteristics were not as good using dried blood smears with blood collected into a solution with EDTA (ethylenediaminetetraacetic acid); use of EDTA blood reduced the sensitivity to 40 percent. Individuals with defined neuroacanthocytosis syndromes had &gt;28 percent acanthocytes (see <a class="local">'Neuroacanthocytosis'</a> below); the reference range for controls was determined to be &lt;6.3 percent.</p><p>Target cells and stomatocytes are RBCs with an abnormal appearance of the central pallor, due to changes in the lipid membrane composition and the surface-to-volume ratio of the cell. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target cells</strong> – Target cells (codocyte is the term for the circulating target cell) have an area of central density (a hyperchromic "bulls-eye") surrounded by a halo of pallor  (<a class="graphic graphic_picture graphicRef80318" href="/d/graphic/80318.html" rel="external">picture 4</a>). </p><p></p><p class="bulletIndent1">Target cells probably circulate as bell-shaped cells called codocytes. Wet prep smears, made using isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> without drying, demonstrate these bell-shaped cells; the target shape seen on a routine dried peripheral blood smear is probably an artifact due to the redundant cell membrane.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stomatocytes</strong> – Stomatocytes (from the root "stoma" meaning mouth; also called hydrocytes) have a mouth-shaped area of central pallor, as illustrated in the images from a peripheral blood smear  (<a class="graphic graphic_picture graphicRef75535" href="/d/graphic/75535.html" rel="external">picture 5</a>) and electron microscopy  (<a class="graphic graphic_picture graphicRef130751" href="/d/graphic/130751.html" rel="external">picture 2</a>). These cells are discussed separately. (See  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Definitions and classification'</a>.) </p><p></p><p>Other imaging methods such as scanning electron microscopy (EM) show the actual three-dimensional structure of target cells and stomatocytes.</p><p class="headingAnchor" id="H937097557"><span class="h1">RBC CHANGES IN LIVER DISEASE</span><span class="headingEndMark"> — </span>Individuals with liver disease have multifactorial changes in red blood cell (RBC) morphologies and causes of anemia that can include the following [<a href="#rid3">3-6</a>].</p><p>Initially, the changes in lipoprotein metabolism can cause accumulation of cholesterol in the RBC membrane that increases surface area, producing target cells [<a href="#rid6">6</a>]. Later, further cholesterol accumulation can cause the membrane to have reduced deformability that leads to spicule formation, producing spur cells, a late change.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target cells</strong> – Target cells are common in liver disease, due to the alterations in lipid physiology. Details of the mechanism are discussed below. (See <a class="local">'Pathophysiology and causes (target cells)'</a> below.)</p><p></p><p class="bulletIndent1">Target cells are not specific for liver disease; they are also seen in thalassemias and other hemoglobinopathies (Hb C, E, and S). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burr cells</strong> – Burr cells (echinocytes) can be seen in liver disease due to the changes in lipid physiology. (See <a class="local">'Causes of burr cells'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spur cells</strong> – Spur cells (a form of acanthocyte (see <a class="local">'Terminology and best practices for viewing'</a> above)) can be seen in liver disease due to the changes in lipid physiology. Studies have found that they generally correlate with advanced hepatocellular disease, which may be associated with 20 to 30 percent acanthocytes in the peripheral blood [<a href="#rid4">4,7,8</a>]. A small study from Greece suggests that the presence of spur cell anemia in patients with alcoholic cirrhosis predicts for a shortened survival and aids in prioritization of such patients for liver transplantation [<a href="#rid9">9</a>]. Resolution of spur cell anemia after liver transplantation further supports a causal relationship [<a href="#rid10">10</a>]. (See <a class="local">'Causes of acanthocytes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microcytosis</strong> – Microcytosis secondary to iron deficiency may occur if there is gastrointestinal bleeding from erosions, ulcers, or varices (which may be exacerbated by coagulation abnormalities). (See  <a class="medical medical_review" href="/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'Causes of microcytosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrocytosis</strong> – Excess alcohol use and liver disease can cause macrocytosis by an unclear mechanism. Macrocytosis can also occur with megaloblastic anemia due to folate deficiency or vitamin B12 deficiency. (See  <a class="medical medical_review" href="/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Overview/common causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolysis</strong> – Advanced liver disease can be associated with moderate to severe hemolysis, which is associated with reticulocytosis (if bone marrow function is adequate). Causes include membrane changes and hypersplenism. (See  <a class="medical medical_review" href="/d/html/7168.html" rel="external">"Non-immune (Coombs-negative) hemolytic anemias in adults", section on 'Liver and kidney disease'</a>.)</p><p></p><p class="bulletIndent1">Splenectomy has also been associated with acanthocytosis and hemolysis. (See <a class="local">'Splenectomy'</a> below.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">BURR CELLS AND ACANTHOCYTES</span></p><p class="headingAnchor" id="H4"><span class="h2">Pathophysiology (burr cells and acanthocytes)</span><span class="headingEndMark"> — </span>The shape of these two types of spiculated cells is thought to be related to changes in the organization of cell membrane components. Although both burr cells and acanthocytes can be seen in liver disease, the mechanisms of their formation appear to differ from each other, as noted in the discussions below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burr cells</strong> – Burr cells (echinocytes) can be easily produced in vitro by incubating red blood cells (RBCs) at high pH, high concentrations of extracellular calcium, low albumin concentration, glass surfaces, or prolonged storage. The figure illustrates the mechanism of formation, which involves formation of small spicules (reversible) and fragmentation/breaking of the ends of the spicules, resulting in membrane loss, which is irreversible  (<a class="graphic graphic_figure graphicRef55556" href="/d/graphic/55556.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1">In kidney disease, a soluble factor can cause reversible burr cell formation. In liver disease, proteins on the RBC surface can bind to abnormal high-density lipoproteins (HDL) and induce the characteristic conformational changes [<a href="#rid11">11</a>]. (See <a class="local">'End-stage kidney disease'</a> below and <a class="local">'Liver disease'</a> below.) </p><p></p><p class="bulletIndent1">Intracellular ATP depletion is associated with burr cell formation. This mechanism may contribute to burr cells seen with pyruvate kinase (PK) deficiency, severe hypophosphatemia, and prolonged storage [<a href="#rid12">12</a>]. (See <a class="local">'Causes of burr cells'</a> below.)</p><p></p><p class="bulletIndent1">In one patient, echinocytes were present in association with a massive splenic hemangioma and disappeared following splenectomy [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acanthocytes</strong> – Acanthocytes result from a combination of changes, including increased RBC membrane cholesterol, increased surface area-to-volume ratio, impaired fluidity of the RBC membrane, reduced ability to withstand membrane tension, and reduced repair/removal of fatty acids damaged by peroxidation [<a href="#rid3">3,14-16</a>]. Increased proteolytic activity in the RBC membrane, possibly due to a circulating factor, and splenic conditioning may also contribute to acanthocyte formation [<a href="#rid3">3,15,17-19</a>]. The RBCs cannot synthesize new phospholipids, and fatty acid damage accumulates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cytoskeletal changes</strong> – Focal changes in the submembrane cytoskeleton are likely to be involved in predisposing to acanthocyte formation. One hypothesis from 2004 suggested that changes in Band 3 are responsible [<a href="#rid20">20</a>]. Changes in the phosphorylation status of Band 3 have also been observed [<a href="#rid21">21</a>]. Band 3 has a significant role in maintaining connections between the RBC membrane and the submembrane cytoskeleton; it is also an anion exchange channel (its other name is AE1). (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics", section on 'Band 3'</a>.)</p><p></p><p class="bulletIndent2">Different genetic variants affecting Band 3 appear to produce different RBC phenotypes, consistent with multiple domains carrying out independent functions. Some variants produce hereditary spherocytosis (HS), a specific 27 base pair deletion causes Southeast Asian ovalocytosis (SAO), and a specific point mutation causes dramatic acanthocytosis and distal renal tubular acidosis. (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis", section on 'Band 3 deficiency due to SLC4A1 variants'</a> and <a class="local">'Band 3/AE1 A858D variant'</a> below and  <a class="medical medical_review" href="/d/html/142822.html" rel="external">"Southeast Asian ovalocytosis (SAO)", section on 'Specific SLC4A1 deletion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lipids</strong> – Membrane lipid abnormalities also contribute to acanthocytosis, as seen in liver disease and familial lipid disorders [<a href="#rid22">22</a>]. (See <a class="local">'RBC changes in liver disease'</a> above and <a class="local">'Chylomicron retention disease'</a> below and  <a class="medical medical_review" href="/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation"</a>.)</p><p></p><p class="bulletIndent2">Accumulated fatty acid damage occurs because the RBC is unable to synthesize new phospholipids. However, the cell can identify and remove peroxidized fatty acid chains that interfere with normal membrane lipid fluidity [<a href="#rid15">15</a>]. When the fatty acid is removed, a lyso-derivative with lytic activity remains, and the missing fatty acid chain must be replaced. This is accomplished using a storage pool of acyl groups present in the cell membrane in the form of acylcarnitine. When needed, the fatty acid (acyl group) is transferred to acyl-CoA and inserted into the potentially lytic lysophospholipid by the enzyme lysophosphocholine acyl transferase (LAT).</p><p></p><p class="bulletIndent2">LAT is inhibited in acanthocytes; it can also be inhibited by heavily loading RBCs with cholesterol in vitro [<a href="#rid15">15</a>]. This suggests that the accumulation of excess cholesterol in RBC membranes in individuals with liver disease may be the first step in acanthocyte formation [<a href="#rid3">3,15,18</a>]. The second step involves extensive remodeling of the RBC in the spleen [<a href="#rid17">17,18</a>]. This differs from the mechanism of burr cell formation in liver disease.</p><p></p><p class="headingAnchor" id="H3824285887"><span class="h2">Causes of burr cells</span><span class="headingEndMark"> — </span>In addition to a drying and storage artifact, there are several diverse causes of burr cells. </p><p class="headingAnchor" id="H3124788796"><span class="h3">Slide artifact</span><span class="headingEndMark"> — </span>Burr cells are often found as artifacts on blood smears. They can be produced in vitro by incubation at high pH or in the presence of high calcium concentrations, exposure to glass surfaces, reduced albumin concentrations, and after prolonged storage. </p><p class="headingAnchor" id="H1687946466"><span class="h3">End-stage kidney disease</span><span class="headingEndMark"> — </span>Burr cells are seen in patients with end-stage kidney disease (ESKD), and echinocytosis appears to be transiently exacerbated during the first 30 minutes of hemodialysis [<a href="#rid23">23-25</a>]. (See  <a class="medical medical_review" href="/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>.)</p><p>Incubation of control RBCs in the plasma of patients with ESKD causes burr cells to form, and incubation of RBCs from patients with ESKD in control plasma causes echinocytosis to resolve [<a href="#rid23">23</a>]. These findings are consistent with echinocytosis being caused by a circulating factor associated with ESKD. </p><p class="headingAnchor" id="H1595749913"><span class="h3">Liver disease</span><span class="headingEndMark"> — </span>(See <a class="local">'RBC changes in liver disease'</a> above.)</p><p class="headingAnchor" id="H483513951"><span class="h3">Vitamin E deficiency</span><span class="headingEndMark"> — </span>Burr cells (and occasional acanthocytes) are a feature of vitamin E deficiency [<a href="#rid26">26</a>]. Previously noted in premature infants due to inadequate dietary vitamin E content, vitamin E deficiency is most likely to be seen in patients who have fat malabsorption, often related to liver disease or cystic fibrosis [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/2582.html" rel="external">"Overview of vitamin E", section on 'Deficiency'</a>.)</p><p class="headingAnchor" id="H753393087"><span class="h3">Pyruvate kinase deficiency</span><span class="headingEndMark"> — </span>Burr cells are occasionally seen in patients with PK deficiency, particularly after splenectomy. They may also be seen with other disorders of the glycolytic pathway, such as glucose-6-phosphate isomerase (GPI) deficiency. (See  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency"</a>.)</p><p class="headingAnchor" id="H1764650504"><span class="h3">Multisystem Inflammatory Syndrome in Children (MIS-C)</span><span class="headingEndMark"> — </span>Burr cells have been described in children with MIS-C, the inflammatory syndrome seen after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). In a series of 20 patients, burr cells were not seen in patients with minimal disease but were identified in 40 percent with severe disease [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3509857019"><span class="h3">Woronet's trait</span><span class="headingEndMark"> — </span>Woronet's trait is a condition described in a single family in 1980 [<a href="#rid30">30</a>]. The proband was a 13-year-old male with marked echinocytosis affecting a small portion of RBCs (5 to 10 percent) that was not explained by testing for common causes of acanthocytosis (RBC enzyme disorders, lipid disorders, cytoskeletal abnormalities, McLeod phenotype). There was mild anemia without hemolysis, and RBC lifespan was normal. His mother and two siblings had similar findings. </p><p class="headingAnchor" id="H903187812"><span class="h2">Causes of acanthocytes</span><span class="headingEndMark"> — </span>Many of the causes of acanthocytes are associated with alterations in lipid profile. A significant number of acanthocytes can be seen in liver disease and neuroacanthocytosis. (See <a class="local">'RBC changes in liver disease'</a> above and <a class="local">'Neuroacanthocytosis'</a> below.)</p><p class="headingAnchor" id="H2746905761"><span class="h3">Liver disease</span><span class="headingEndMark"> — </span>(See <a class="local">'RBC changes in liver disease'</a> above.)</p><p class="headingAnchor" id="H3024027573"><span class="h3">Hypothyroidism</span><span class="headingEndMark"> — </span>Approximately 20 percent of patients with hypothyroidism have a small number of acanthocytes (0.5 to 2 percent) on peripheral blood smears; however, occasional patients have more prominent acanthocytosis [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Anemia'</a>.)</p><p>Thyroid function testing may be indicated when acanthocytes are seen in the absence of any other apparent cause [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H2998439740"><span class="h3">Drug-induced</span><span class="headingEndMark"> — </span>Transient acanthocytosis, with or without hemolytic anemia, has been reported with some medications. Alterations in lipid profiles may be responsible; however, a causal relationship has not been established.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">Alectinib</a> – Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor. In a series of 43 patients treated with alectinib for advanced non-small cell lung cancer (NSCLC), 41 (95 percent) developed acanthocytosis [<a href="#rid34">34</a>]. Reduced binding of eosin-5-maleimide (EMA), consistent with loss of band 3, was seen in all cases. Anemia was present 73 percent, but only 11 percent had documented hemolysis as the cause. </p><p></p><p class="bulletIndent1">Additional case reports have described similar findings [<a href="#rid35">35</a>]. The mechanism by which <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a> causes acanthocytosis, and the reason that some patients develop hemolysis and others do not, remain to be determined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostaglandins</strong> – Acanthocytosis and hemolytic anemia followed administration of high-dose <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> for medical termination of pregnancy in a 21-year-old [<a href="#rid36">36</a>]. Acanthocytosis resolved spontaneously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Acanthocytosis and hemolytic anemia (hemoglobin 6.7 g/dL) was reported in a 67-year-old patient treated with <a class="drug drug_general" data-topicid="8949" href="/d/drug information/8949.html" rel="external">atorvastatin</a>; the low density lipoprotein (LDL) cholesterol decreased to an extremely low level (6 mg/dL) [<a href="#rid37">37</a>]. Acanthocytosis resolved 11 days after stopping the drug.</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Anorexia nervosa</span><span class="headingEndMark"> — </span>Patients with anorexia nervosa may have acanthocytosis [<a href="#rid38">38,39</a>]. The mechanisms responsible have not been defined, but changes in plasma lipids or RBC membrane proteins may be involved. The anemia seen in patients with anorexia nervosa is more often hypoplastic and not hemolytic or related to the changes in RBC morphology. The acanthocytosis is reversible with improvement in nutritional status [<a href="#rid38">38,40</a>].</p><p class="headingAnchor" id="H3810345963"><span class="h3">Myelodysplastic syndromes</span><span class="headingEndMark"> — </span>Some patients with myelodysplastic syndromes have 5 to 10 percent acanthocytes; in some cases, acanthocytosis may be the primary reason for referral [<a href="#rid41">41</a>]. </p><p>More common hematologic findings include dysplastic hematopoiesis with macrocytic RBCs. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Blood smear'</a>.) </p><p class="headingAnchor" id="H1433777114"><span class="h3">Splenectomy</span><span class="headingEndMark"> — </span>Removal of the spleen has been associated with acanthocytosis, as well as other RBC changes including Howell-Jolly bodies (nuclear fragments), which are very common, and target cells, which are variable. Hypersplenism associated with liver disease can produce similar changes. (See <a class="local">'Pathophysiology and causes (target cells)'</a> below and <a class="local">'RBC changes in liver disease'</a> above.)</p><p>Some individuals with post-splenectomy acanthocytosis have hemolysis and others do not. Disappearance of acanthocytes after regrowth of an accessory spleen further supports a causal relationship [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H2065600379"><span class="h3">Neuroacanthocytosis</span><span class="headingEndMark"> — </span>Neuroacanthocytosis (previously called Levine-Critchley syndrome) encompasses several rare genetic disorders with acanthocytes in the peripheral blood, neuromuscular manifestations, and neurodegeneration. The presence of acanthocytes on the blood smear may be helpful in suggesting the diagnosis. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis"</a>.)</p><p>These disorders include [<a href="#rid21">21,43-46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abetalipoproteinemia and hypobetalipoproteinemia</p><p class="bulletIndent1"><span class="glyph">●</span>Chorea-acanthocytosis (ChAc)</p><p class="bulletIndent1"><span class="glyph">●</span>McLeod syndrome (MLS)</p><p class="bulletIndent1"><span class="glyph">●</span>Pantothenate-kinase associated neurodegeneration (PKAN)</p><p class="bulletIndent1"><span class="glyph">●</span>Huntington's disease-like 2 (HDL2)</p><p></p><p>The percentage of acanthocytes is variable; in one study involving 100 patients with neuroacanthocytosis that evaluated optimally prepared blood smears (see <a class="local">'Terminology and best practices for viewing'</a> above), all had &gt;28 percent acanthocytes [<a href="#rid2">2</a>]. The degree of neurologic impairment does not correlate with the degree of acanthocytosis on the peripheral blood smear. Mild hemolytic anemia is sometimes seen but is not invariably present. </p><p>The basis for acanthocytosis in these disorders is not clear, and laboratory efforts to explore the mechanism of acanthocyte formation have been unproductive [<a href="#rid47">47-49</a>]. The specific gene variants and evaluation and treatment of these disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Chylomicron retention disease</span><span class="headingEndMark"> — </span>Chylomicron retention disease (also called Anderson disease) is a rare autosomal recessive disorder characterized by low LDL-cholesterol, severe deficiency of vitamin E and other fat-soluble vitamins, and impaired chylomicron production. Mild acanthocytosis has been reported [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation", section on 'Chylomicron retention disease'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Blood group abnormalities</span><span class="headingEndMark"> — </span>Acanthocytes have been associated with two abnormalities of blood group systems: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>McLeod syndrome</strong> – McLeod syndrome is a type of neuroacanthocytosis. (See <a class="local">'Neuroacanthocytosis'</a> above and  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Mcleod syndrome'</a>.)</p><p></p><p class="bulletIndent1">The RBC phenotype is associated with uniformly weak Kell system antigens, due to pathogenic variants in the <em>XK</em> gene, the product of which is required for membrane anchoring of the Kell antigens. (See  <a class="medical medical_review" href="/d/html/7924.html" rel="external">"Red blood cell antigens and antibodies", section on 'Kell antigens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lutheran null phenotype</strong> – The Lutheran blood group system has two antigens, a and b. The most common cause of the null Lutheran phenotype, Lu(a-b-), is the presence of an inhibitor called "In(Lu)"; this inhibitor partially suppresses expression of Lu(a) and Lu(b), making them undetectable by standard agglutination tests [<a href="#rid51">51-53</a>]. The In(Lu) inhibitor is encoded by the <em>INLU</em> gene. In addition to Lutheran antigens, it also inhibits expression of other cell surface proteins such as CD44 [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/7924.html" rel="external">"Red blood cell antigens and antibodies", section on 'Lutheran blood group system'</a>.)</p><p></p><p class="bulletIndent1">Approximately 1 in 5000 individuals inherits this dominantly acting inhibitor [<a href="#rid51">51</a>]. Affected patients have abnormally shaped RBCs but no hemolysis. RBC morphology may be normal, poikilocytic, or acanthocytic [<a href="#rid51">51,54</a>].</p><p></p><p class="headingAnchor" id="H2544008802"><span class="h3">Band 3/AE1 A858D variant</span><span class="headingEndMark"> — </span>Pathogenic variants in the <em>SLC4A1</em> gene, which encodes the RBC membrane protein Band 3 (also called AE1 [anion exchanger 1]), are associated with hereditary spherocytosis. (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis"</a>.)</p><p>The specific Band3/AE1 variant A858D, which results in a single amino acid substitution, aspartic acid instead of the normal alanine at amino acid 858, has been associated with acanthocytosis/spur cell anemia in multiple unrelated individuals.:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild hemolytic anemia and acanthocytosis in seven children who were homozygous for the A858D variant and had compensated hemolytic anemia, metabolic acidosis, and failure to thrive [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic anemia, distal renal tubular acidosis (RTA), and acanthocytosis in two unrelated individuals (ages six and 15 years) who were homozygous for the A858D variant [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compensated hemolysis with 70 to 85 percent acanthocytes, along with profound distal RTA (with hypokalemia-induced quadriparesis), in a 17-year-old child of consanguineous parents who was homozygous for the A858D variant [<a href="#rid57">57</a>].</p><p></p><p>The mechanism of acanthocytosis with the A858D variant is unexplained. Band 3/AE1 has several functions, include providing cohesion between the RBC membrane and underlying cytoskeleton, facilitating bicarbonate exchange, and linking other proteins such as blood group antigens to the RBC surface. </p><p>Other specific variants in <em>SLC4A1 </em>cause distinct syndromes including Southeast Asian Ovalocytosis (SAO) and distal (type 1) RTA. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics", section on 'Band 3'</a> and  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) RTA'</a> and  <a class="medical medical_review" href="/d/html/142822.html" rel="external">"Southeast Asian ovalocytosis (SAO)"</a>.)</p><p>Another report described several patients with hereditary spherocytosis (HS) due to variants in the gene that encodes spectrin, several of which are associated with autosomal dominant HS and frequent acanthocytes (8 to 15 percent) [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis", section on 'Overview of the proteins and genes involved'</a>.)</p><p class="headingAnchor" id="H3411012178"><span class="h2">Laboratory testing unexplained burr cells or acanthocytes</span><span class="headingEndMark"> — </span>Burr cells and acanthocytes are seen in a number of disorders that are outlined above. (See <a class="local">'RBC changes in liver disease'</a> above and <a class="local">'Causes of burr cells'</a> above and <a class="local">'Causes of acanthocytes'</a> above.) </p><p>These abnormalities are usually not associated with hemolysis or a shortened RBC lifespan, with the exception of spur cells in liver disease. If the underlying cause is known, generally no additional testing is needed. However, if the underlying cause is not known, these findings may indicate the possibility of an underlying condition that may require evaluation or treatment. (See <a class="local">'Management'</a> below.)</p><p>If the cause of burr cells or acanthocytes is known, no additional evaluation is required. </p><p>If burr cells or acanthocytes are identified in a patient without a known underlying cause, the following may be reasonable for the initial evaluation; this generally can be performed by the primary care clinician:</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the complete blood count (CBC) over time, to determine if anemia is present and if it is worsening.</p><p class="bulletIndent1"><span class="glyph">●</span>Repeat an additional freshly prepared peripheral blood smear with manual review. Storage artifact is a common cause of burr cells. (See <a class="local">'Terminology and best practices for viewing'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Review medications to identify possible drug-induced causes and determine the temporal relationship.</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain hemolysis testing with reticulocyte count, bilirubin, lactate dehydrogenase (LDH), and haptoglobin  (<a class="graphic graphic_table graphicRef126234" href="/d/graphic/126234.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain liver and kidney function tests.</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain thyroid function testing (for acanthocytes).</p><p class="bulletIndent1"><span class="glyph">●</span>Obtain a lipid panel, if age-appropriate and not recently performed.</p><p></p><p>Other testing may be appropriate if initial testing is unrevealing or if there is a positive family history of the morphologic changes; this testing is probably best conducted by the specialist (hematologist, lipid specialist, or other specialist depending on patient age and presentation):</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the blood smear for other abnormalities</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the lipid profile</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for other causes of hemolytic anemia (see  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin E level (for burr cells) (see  <a class="medical medical_review" href="/d/html/2582.html" rel="external">"Overview of vitamin E", section on 'Deficiency'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pyruvate kinase (PK) activity (for burr cells) (see  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency", section on 'PK-specific testing: Where and how to test'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing for specific disorders as suggested by laboratory studies</p><p></p><p>The urgency of evaluation (and whether certain tests are performed sequentially or simultaneously) depends on the patient's clinical status and findings on the initial history, examination, and baseline laboratory testing. Some testing listed above is specific for only burr cells or only acanthocytes, but if there is a question about the morphology (or a mixture of morphologies) it may be appropriate for both types of cells. </p><p class="headingAnchor" id="H21"><span class="h1">TARGET CELLS</span></p><p class="headingAnchor" id="H22"><span class="h2">Pathophysiology and causes (target cells)</span><span class="headingEndMark"> — </span>The shape of these cells is thought to be related to changes in the ratio of cell membrane to cytoplasmic volume (the surface area-to-volume ratio), with excess, redundant cell membrane causing the target appearance inside the region of central pallor. The increase in surface area-to-volume ratio can be due to increased plasma membrane or decreased intracellular volume.</p><p class="headingAnchor" id="H1214698000"><span class="h3">Increased membrane</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – The main cause of increased plasma membrane occurs is obstructive liver disease. (See <a class="local">'RBC changes in liver disease'</a> above.)</p><p></p><p class="bulletIndent1">The mechanism involves increased bile salts, which inhibit the enzyme lecithin-cholesterol acyltransferase (LCAT). LCAT normally esterifies cholesterol to cholesterol esters and phosphatidylcholines (lecithins) to lysophosphatidylcholines on the surface of high-density lipoproteins (HDLs) [<a href="#rid59">59</a>]. When LCAT is reduced, excess unesterified cholesterol and phospholipids increase, with a greater proportional increase in cholesterol [<a href="#rid3">3</a>]. This in turn increases the ratio of cholesterol to phospholipids incorporated into the RBC plasma membrane bilayer [<a href="#rid60">60-62</a>]. (See  <a class="medical medical_review" href="/d/html/4565.html" rel="external">"Lipoprotein classification, metabolism, and role in atherosclerosis"</a>.)</p><p></p><p class="bulletIndent1">The central role of abnormal plasma lipids in the formation of target cells is demonstrated by two laboratory observations. Incubation of RBCs in plasma from patients with obstructive liver disease causes target cells to form in vitro, and incubation of target cells in plasma from patients without liver disease causes loss of the target cell appearance. A clinical correlate is that patients with hereditary spherocytosis who develop gallstones with obstructive jaundice also experience reduced hemolysis and increased osmotic fragility due to increased RBC membrane and improved surface-to-volume ratio [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics", section on 'Surface area to volume ratio (SA/V)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less common causes:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Splenectomy</strong> – Removal of the spleen has been associated with variable target cells, as well as acanthocytes and other RBC changes including Howell-Jolly bodies (nuclear fragments), which are very common, and target cells, which are variable. (See <a class="local">'RBC changes in liver disease'</a> above and <a class="local">'Causes of acanthocytes'</a> above.)</p><p></p><p class="bulletIndent2">Normally, the spleen removes excess membrane from red blood cells (RBCs), a process called "splenic conditioning" [<a href="#rid64">64,65</a>]. The exact mechanism is not defined, although the reduction in RBC lipid content suggests that lipases may be involved. In the first few weeks following splenectomy, target cells appear, reaching levels of 2 to 10 percent. The cells have increased membrane, increased surface-to-volume ratio, and reduced osmotic fragility [<a href="#rid64">64,66</a>]. These RBCs may eventually lose their excess lipid by conditioning in other sites, leading to the gradual disappearance of target cells.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hereditary LCAT deficiency</strong> – Hereditary LCAT deficiency is a rare autosomal recessive disorder caused by homozygous pathogenic variants in the <em>LCAT </em>gene. Clinical manifestations include normocytic anemia with prominent target cells [<a href="#rid67">67-71</a>]. HDL cholesterol is low, and there is chronic kidney disease with proteinuria [<a href="#rid67">67,68,71</a>]. Some individuals have corneal opacities, leading to the designation "fish eye syndrome." (See  <a class="medical medical_review" href="/d/html/4560.html" rel="external">"HDL cholesterol: Clinical aspects of abnormal values", section on 'Inherited causes'</a>.)</p><p></p><p class="bulletIndent1">The mechanism of target cell formation in hereditary LCAT deficiency is similar to liver disease. </p><p></p><p class="headingAnchor" id="H1460222352"><span class="h3">Decreased volume</span><span class="headingEndMark"> — </span>Decreased intracellular volume occurs in conditions in which intracellular hemoglobin is decreased [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalassemia</strong> – Alpha and beta thalassemia can both cause target cells when severe (especially transfusion-dependent beta thalassemia and hemoglobin H disease). (See  <a class="medical medical_review" href="/d/html/7090.html" rel="external">"Pathophysiology of thalassemia", section on 'Terminology and disease classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hemoglobinopathies</strong> – Target cells (or target-like cells) can also be seen in sickle cell disease and hemoglobin C (Hb C), Hb D, and Hb E disease. (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron deficiency</strong> – Iron deficiency can cause target cells, especially when iron deficiency anemia is severe. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Stages of iron deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xerocytosis</strong> – Xerocytosis is a less common cause of decreased intracellular volume. Xerocytes are dense, hyperchromic RBCs caused by solute loss that induces osmotic water loss. RBC dehydration also usually produces target cells, Hereditary xerocytosis (HX) can be caused by pathogenic variants in one of several genes that control RBC hydration. (See  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Xerocyte formation'</a>.) </p><p></p><p class="headingAnchor" id="H3656241156"><span class="h2">Laboratory testing target cells</span><span class="headingEndMark"> — </span>In many cases, the condition causing target cells is already known, and no further evaluation is needed. </p><p>If target cells are found in an individual for whom the cause is not known, testing is appropriate to identify the cause. This testing can generally be performed by the primary care clinician, although specialist input may be appropriate if there is uncertainly in deciding which tests to perform or in interpreting the results. </p><p>The first step is to review the patient's clinical status and the complete blood count (CBC), including RBC indices, RBC count, and other RBC morphologies.</p><p>Additional laboratory testing after review of the CBC may include the following: this generally can be performed by the primary care clinician:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron studies</strong> – Iron studies are especially important in premenopausal females, as well as individuals with microcytosis and a low RBC count and prior to performing hemoglobin analysis. (See  <a class="medical medical_review" href="/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin analysis</strong> – Hemoglobin analysis, typically using a protein-based method, is especially important in individuals with suspected hemoglobinopathy or thalassemia, including those with anemia since birth or early childhood and with an increased RBC count. Iron studies should be performed, and iron deficiency corrected, prior to obtaining this testing. Routine iron supplementation should not be administered without iron studies, as individuals with thalassemia often have iron overload. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Protein chemistry methods'</a> and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Patient with suspected thalassemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver function testing</strong> – Liver function tests are especially important in older individuals with risk factors for liver disease, individuals with new onset target cells, and those who lack evidence of iron deficiency or thalassemia (absence of microcytosis, normal or increased iron stores, normal RBC count, normal hemoglobin analysis). (See  <a class="medical medical_review" href="/d/html/3573.html" rel="external">"Overview of liver biochemical tests"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipid panel</strong> – A lipid panel is appropriate if there are signs of liver disease or if iron studies, hemoglobin analysis, and liver function tests are unrevealing. Many individuals will already have had a lipid panel done for primary prevention of cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a> and  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Genetic testing for LCAT deficiency is only appropriate if there is a positive family history of the disorder, a very low HDL cholesterol, or other clinical features associated with the disorder. (See <a class="local">'Increased membrane'</a> above and  <a class="medical medical_review" href="/d/html/4560.html" rel="external">"HDL cholesterol: Clinical aspects of abnormal values", section on 'Inherited causes'</a>.)</p><p></p><p class="headingAnchor" id="H2084179546"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Not all disorders associated with burr cells, acanthocytes, or target cells cause hemolysis or hemolytic anemia. </p><p class="bulletIndent1"><span class="glyph">●</span>If hemolysis and anemia are absent, no specific treatment is required, although treatment may be indicated for the underlying disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a specific underlying cause is found, decisions about treatment depend on the severity of hemolytic anemia and the other manifestations of the underlying disorder. Specific management recommendations for these disorders are provided in separate topic reviews on each disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As long as chronic hemolysis is occurring, we suggest <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation. A typical dose is 1 mg daily. This can be omitted if the individual is consuming a folate-rich or folic acid-supplemented diet. This practice is based on the known increased consumption of folates when erythropoiesis is increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attention to other conditions that can cause anemia is also important if present, especially the more common causes of anemia including vitamin B12 and folate deficiencies, iron deficiency, and anemia of chronic disease/anemia of inflammation (ACD/AI). (See  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a> and  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On occasion, spur cell hemolytic anemia is severe enough to necessitate consideration of splenectomy. The operative morbidity in such cases is considerable, because there may be concomitant thrombocytopenia and leukopenia due to hypersplenism or other conditions. Splenectomy is generally avoided unless hemolytic anemia is severe and does not improve with other interventions. The final decision is individualized in consultation with a specialist in the specific underlying disorder, to ensure that nonsurgical options have been appropriately considered and optimally used.</p><p></p><p class="bulletIndent1">Severe liver disease can also cause abnormalities in hemostasis and intolerance to anesthesia. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Abnormalities of the red blood cell (RBC) membrane can lead to abnormal RBC morphologies. Burr cells (echinocytes) have uniform small spicules  (<a class="graphic graphic_picture graphicRef121023" href="/d/graphic/121023.html" rel="external">picture 1</a>); acanthocytes have irregular large spicules  (<a class="graphic graphic_picture graphicRef120809" href="/d/graphic/120809.html" rel="external">picture 3</a>); and target cells  (<a class="graphic graphic_picture graphicRef80318" href="/d/graphic/80318.html" rel="external">picture 4</a>) have a "bulls-eye" area of central density within the region of central pallor. (See <a class="local">'Terminology and best practices for viewing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Burr cells</strong> <strong>and acanthocytes</strong> – Burr cells can be induced in vitro and in vivo by extracellular factors (pH, calcium, glass, circulating substances in kidney or liver disease); the figure illustrates initial reversible and later irreversible steps  (<a class="graphic graphic_figure graphicRef55556" href="/d/graphic/55556.html" rel="external">figure 1</a>). Acanthocytes can be caused by changes that alter RBC membrane fluidity, including increased membrane cholesterol and reduced repair/removal of fatty acids. A specific Band 3 domain may be involved.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target cells</strong> – Target cells are caused by increased surface area-to-volume ratio, which can occur via increased plasma membrane or decreased intracellular volume. Increased membrane is often due to lipid disorders; decreased volume is often due to hemoglobin disorders (iron deficiency anemia and thalassemia). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Often the cause will be known from the history. If unknown, it is worthwhile to conduct an evaluation of medical conditions, syndromic features, and prior splenectomy. The complete blood count (CBC) and RBC indices should be reviewed. Liver disease can cause all three morphologies. (See <a class="local">'RBC changes in liver disease'</a> above.)</p><p></p><p class="bulletIndent1">Causes include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Burr cells</strong> – (See <a class="local">'Causes of burr cells'</a> above and <a class="local">'Laboratory testing unexplained burr cells or acanthocytes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Laboratory artifact</strong> – Repeat blood smear with freshly prepared blood sample.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Kidney or liver disease </strong>– Kidney and liver function tests.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Vitamin E deficiency</strong> – Vitamin E level.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pyruvate kinase (PK) deficiency</strong> – PK activity. </p><p class="bulletIndent3"><span class="glyph">-</span><strong>Multisystem Inflammatory Syndrome in Children (MIS-C)</strong> – Evaluation for symptoms. (See  <a class="medical medical_review" href="/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.) .</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acanthocytes</strong> – (See <a class="local">'Causes of acanthocytes'</a> above and <a class="local">'Laboratory testing unexplained burr cells or acanthocytes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Liver disease</strong> – Liver function tests.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypothyroidism</strong> – Thyroid function tests.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Drug-induced</strong> – Medication review, lipid panel.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Anorexia nervosa</strong> – Clinical evaluation.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Myelodysplasia</strong> – Hematologist evaluation if suspected.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Rare disorders</strong> (neuroacanthocytosis, chylomicron retention disease, blood group abnormalities, Band 3 A858D variant) – Specific testing listed above. (See <a class="local">'Laboratory testing unexplained burr cells or acanthocytes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target cells</strong> – (See <a class="local">'Target cells'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Iron deficiency</strong> – Iron studies.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Thalassemia</strong> – Hemoglobin analysis (after iron studies are done and iron deficiency corrected if present).</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hemoglobinopathy</strong> – Hemoglobin analysis, particularly for Hb C, D, and E.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Liver disease</strong> – Liver function tests.</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Lecithin-cholesterol acyltransferase (LCAT) deficiency</strong> – Lipid panel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Isolated morphologic changes without anemia or hemolysis may not require treatment, although treatment of the condition causing the changes may be appropriate. Causes of anemia such as vitamin B12, folate, or iron deficiency should be reviewed and treated as required. </p><p></p><p class="bulletIndent1">For chronic hemolytic anemia, we suggest <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Individuals with a folate-rich or folic acid-supplemented diet may reasonably omit folic acid if they are not folate deficient. </p><p></p><p class="bulletIndent1">Splenectomy is generally avoided unless hemolytic anemia is severe and does not improve with other interventions. (See <a class="local">'Management'</a> above.)</p><p></p><p class="headingAnchor" id="H3291147021"><span class="h1">ACKNOWLEDGMENTS</span></p><p>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Anoop P, Parker-Williams J. Morphological diagnosis of abetalipoproteinemia and the importance of a freshly prepared peripheral smear. Eur J Haematol 2009; 83:606.</a></li><li><a class="nounderline abstract_t">Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients. J Neurol 2005; 252:84.</a></li><li><a class="nounderline abstract_t">Cooper RA. Hemolytic syndromes and red cell membrane abnormalities in liver disease. Semin Hematol 1980; 17:103.</a></li><li><a class="nounderline abstract_t">SMITH JA, LONERGAN ET, STERLING K. SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS. N Engl J Med 1964; 271:396.</a></li><li><a class="nounderline abstract_t">Grahn EP, Dietz AA, Stefani SS, Donnelly WJ. Burr cells, hemolytic anemia and cirrhosis. Am J Med 1968; 45:78.</a></li><li><a class="nounderline abstract_t">Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50:216.</a></li><li><a class="nounderline abstract_t">Salvioli G, Rioli G, Lugli R, Salati R. Membrane lipid composition of red blood cells in liver disease: regression of spur cell anaemia after infusion of polyunsaturated phosphatidylcholine. Gut 1978; 19:844.</a></li><li><a class="nounderline abstract_t">Patel A, Tillman BF. Spur-Cell Hemolytic Anemia. N Engl J Med 2022; 386:e6.</a></li><li><a class="nounderline abstract_t">Vassiliadis T, Mpoumponaris A, Vakalopoulou S, et al. Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. Hepatol Res 2010; 40:161.</a></li><li><a class="nounderline abstract_t">Chitale AA, Sterling RK, Post AB, et al. Resolution of spur cell anemia with liver transplantation: a case report and review of the literature. Transplantation 1998; 65:993.</a></li><li><a class="nounderline abstract_t">Owen JS, Brown DJ, Harry DS, et al. Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins. J Clin Invest 1985; 76:2275.</a></li><li><a class="nounderline abstract_t">Melvin JD, Watts RG. Severe hypophosphatemia: a rare cause of intravascular hemolysis. Am J Hematol 2002; 69:223.</a></li><li><a class="nounderline abstract_t">Altomare I, Desman G, Aledort LM. Echinocytosis--an unusual manifestation of hemangioma. Am J Hematol 2006; 81:532.</a></li><li><a class="nounderline abstract_t">Terada N, Fujii Y, Ueda H, et al. Ultrastructural changes of erythrocyte membrane skeletons in chorea-acanthocytosis and McLeod syndrome revealed by the quick-freezing and deep-etching method. Acta Haematol 1999; 101:25.</a></li><li><a class="nounderline abstract_t">Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia. Blood 1996; 87:3489.</a></li><li><a class="nounderline abstract_t">Allen DW, Manning N. Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes. Blood 1994; 84:1283.</a></li><li><a class="nounderline abstract_t">Shohet SE. Editorial: "Acanthocytogenesis"--or how the red cell won its spurs. N Engl J Med 1974; 290:1316.</a></li><li><a class="nounderline abstract_t">Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease. N Engl J Med 1974; 290:1279.</a></li><li><a class="nounderline abstract_t">Olivieri O, Guarini P, Negri M, et al. Increased proteolytic activity of erythrocyte membrane in spur cell anaemia. Br J Haematol 1988; 70:483.</a></li><li><a class="nounderline abstract_t">Wong P. A basis of the acanthocytosis in inherited and acquired disorders. Med Hypotheses 2004; 62:966.</a></li><li><a class="nounderline abstract_t">De Franceschi L, Bosman GJ, Mohandas N. Abnormal red cell features associated with hereditary neurodegenerative disorders: the neuroacanthocytosis syndromes. Curr Opin Hematol 2014; 21:201.</a></li><li><a class="nounderline abstract_t">Cloos AS, Daenen LGM, Maja M, et al. Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia - A Case Study. Front Physiol 2021; 12:638027.</a></li><li><a class="nounderline abstract_t">Hasler CR, Owen GR, Brunner W, Reinhart WH. Echinocytosis induced by haemodialysis. Nephrol Dial Transplant 1998; 13:3132.</a></li><li><a class="nounderline abstract_t">AHERNE WA. The burr red cell and azotaemia. J Clin Pathol 1957; 10:252.</a></li><li><a class="nounderline abstract_t">LOGE JP, LANGE RD, MOORE CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958; 24:4.</a></li><li><a class="nounderline abstract_t">Cynamon HA, Isenberg JN, Gustavson LP, Gourley WK. Erythrocyte lipid alterations in pediatric cholestatic liver disease: spur cell anemia of infancy. J Pediatr Gastroenterol Nutr 1985; 4:542.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Guggenheim MA, Iannaccone ST, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med 1985; 313:1580.</a></li><li><a class="nounderline abstract_t">Muller DP, Lloyd JK, Bird AC. Long-term management of abetalipoproteinaemia. Possible role for vitamin E. Arch Dis Child 1977; 52:209.</a></li><li><a class="nounderline abstract_t">Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest 2020; 130:5967.</a></li><li><a class="nounderline abstract_t">Beutler E, West C, Tavassoli M, Grahn E. The Woronets trait: a new familial erythrocyte anomaly. Blood Cells 1980; 6:281.</a></li><li><a class="nounderline abstract_t">Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med 1976; 45:101.</a></li><li><a class="nounderline abstract_t">Wardrop C, Hutchison HE. Red-cell shape in hypothyroidism. Lancet 1969; 1:1243.</a></li><li><a class="nounderline abstract_t">Perillie PE, Tembrevilla C. Letter: Red-cell changes in hypothyroidism. Lancet 1975; 2:1151.</a></li><li><a class="nounderline abstract_t">Kuzich JA, Heynemann S, Geoghegan N, et al. Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding. Pathology 2021; 53:608.</a></li><li><a class="nounderline abstract_t">Legland Ép Dejean AM, Plantamura J, Arnoux I, et al. Acanthocytosis in an alectinib-treated patient. Br J Haematol 2022; 197:131.</a></li><li><a class="nounderline abstract_t">Filippini A, Villa G, Corrocher R, De Franceschi L. Acute hemolytic anemia with acanthocytosis associated with high-dose misoprostol for medical abortion. Ann Emerg Med 2007; 50:289.</a></li><li><a class="nounderline abstract_t">Pacheco JM, Yilmaz M, Rice L. How low is too low: Statin induced hemolysis. Am J Hematol 2016; 91:267.</a></li><li><a class="nounderline abstract_t">Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J 1983; 76:1008.</a></li><li><a class="nounderline abstract_t">Mant MJ, Faragher BS. The haematology of anorexia nervosa. Br J Haematol 1972; 23:737.</a></li><li><a class="nounderline abstract_t">Takeshita J, Arai Y, Hirose N, et al. Abetalipoproteinemia-like lipid profile and acanthocytosis in a young woman with anorexia nervosa. Am J Med Sci 2002; 324:281.</a></li><li><a class="nounderline abstract_t">Doll DC, List AF, Dayhoff DA, et al. Acanthocytosis associated with myelodysplasia. J Clin Oncol 1989; 7:1569.</a></li><li><a class="nounderline abstract_t">Müller U, Röthlin M. [Splenic neoformation following trauma-induced splenectomy--diagnosis and function]. Swiss Surg 1995; :230.</a></li><li><a class="nounderline abstract_t">Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol 2005; 18:386.</a></li><li><a class="nounderline abstract_t">Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92.</a></li><li><a class="nounderline abstract_t">Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci 2005; 229-230:171.</a></li><li><a class="nounderline abstract_t">Lausch E, Yoshimi A. Acanthocytosis: a key feature for the diagnosis of abetalipoproteinemia. Blood 2023; 141:3231.</a></li><li><a class="nounderline abstract_t">Adjobo-Hermans MJ, Cluitmans JC, Bosman GJ. Neuroacanthocytosis: Observations, Theories and Perspectives on the Origin and Significance of Acanthocytes. Tremor Other Hyperkinet Mov (N Y) 2015; 5:328.</a></li><li><a class="nounderline abstract_t">Lupo F, Tibaldi E, Matte A, et al. A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis. Blood 2016; 128:2976.</a></li><li><a class="nounderline abstract_t">Cluitmans JC, Tomelleri C, Yapici Z, et al. Abnormal red cell structure and function in neuroacanthocytosis. PLoS One 2015; 10:e0125580.</a></li><li><a class="nounderline abstract_t">Lesesve JF, Perrin J, Georges A, Morali A. Acanthocytosis in Anderson's disease. Br J Haematol 2009; 145:1.</a></li><li><a class="nounderline abstract_t">Udden MM, Umeda M, Hirano Y, Marcus DM. New abnormalities in the morphology, cell surface receptors, and electrolyte metabolism of In(Lu) erythrocytes. Blood 1987; 69:52.</a></li><li><a class="nounderline abstract_t">Telen MJ, Eisenbarth GS, Haynes BF. Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J Clin Invest 1983; 71:1878.</a></li><li><a class="nounderline abstract_t">Telen MJ. Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. Transfus Clin Biol 1995; 2:291.</a></li><li class="breakAll">Telen MJ. The Lutheran antigens and proteins affected by Lutheran regulatory genes. In: Protein Blood Group Antigens of the Human Red Cell: Structure, Function and Clinical Significance, Agre PC, Cartron JP (Eds), Johns Hopkins University Press, Baltimore 1992. p.70.</li><li><a class="nounderline abstract_t">Fawaz NA, Beshlawi IO, Al Zadjali S, et al. dRTA and hemolytic anemia: first detailed description of SLC4A1 A858D mutation in homozygous state. Eur J Haematol 2012; 88:350.</a></li><li><a class="nounderline abstract_t">Shmukler BE, Kedar PS, Warang P, et al. Hemolytic anemia and distal renal tubular acidosis in two Indian patients homozygous for SLC4A1/AE1 mutation A858D. Am J Hematol 2010; 85:824.</a></li><li><a class="nounderline abstract_t">Knox-Macaulay HH, Rehman JU, Al Zadjali S, et al. Idiopathic thrombocytopenic purpura and hypokalaemic dRTA with compensated haemolysis and striking acanthocytosis in a band 3 (SLC4A1/AE1) A858D homozygote. Ann Hematol 2013; 92:553.</a></li><li><a class="nounderline abstract_t">Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.</a></li><li><a class="nounderline abstract_t">Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000; 1529:245.</a></li><li><a class="nounderline abstract_t">Cooper RA, Jandl JH. Bile salts and cholesterol in the pathogenesis of target cells in obstructive jaundice. J Clin Invest 1968; 47:809.</a></li><li><a class="nounderline abstract_t">Cooper RA, Diloy Puray M, Lando P, Greenverg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest 1972; 51:3182.</a></li><li><a class="nounderline abstract_t">Neerhout RC. Abnormalities of erythrocyte stromal lipids in hepatic disease. J Lab Clin Med 1968; 71:438.</a></li><li><a class="nounderline abstract_t">Cooper RA, Jandl JH. The role of membrane lipids in the survival of red cells in hereditary spherocytosis. J Clin Invest 1969; 48:736.</a></li><li><a class="nounderline abstract_t">de Haan LD, Werre JM, Ruben AM, et al. Alterations in size, shape and osmotic behaviour of red cells after splenectomy: a study of their age dependence. Br J Haematol 1988; 69:71.</a></li><li><a class="nounderline abstract_t">Singer K, Weisz L. The life cycle of the erythrocyte after splenectomy and the problems of splenic hemolysis and target cell formation. Am J Med Sci 1945; 210:301.</a></li><li><a class="nounderline abstract_t">Singer K, Miller EB, et al. Hematologic changes following splenectomy in man, with particular reference to target cells, hemolytic index, and lysolecithin. Am J Med Sci 1941; 202:171.</a></li><li><a class="nounderline abstract_t">Funke H, von Eckardstein A, Pritchard PH, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991; 88:4855.</a></li><li><a class="nounderline abstract_t">Funke H, von Eckardstein A, Pritchard PH, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest 1993; 91:677.</a></li><li><a class="nounderline abstract_t">Gjone E, Torsvik H, Norum KR. Familial plasma cholesterol ester deficiency. A study of the erythrocytes. Scand J Clin Lab Invest 1968; 21:327.</a></li><li><a class="nounderline abstract_t">Norum KR, Gjone E. The influence of plasma from patients with familial plasma lecithin: cholesterol acyltransferase deficiency on the lipid pattern of erythrocytes. Scand J Clin Lab Invest 1968; 22:94.</a></li><li><a class="nounderline abstract_t">Frohlich J, Godolphin WJ, Reeve CE, Evelyn KA. Familial LCAT deficiency. Report of two patients from a Canadian family of Italian and Swedish descent. Scand J Clin Lab Invest Suppl 1978; 150:156.</a></li><li class="breakAll">Gallagher PG, Forget BG, Lux SE. Disorders of the erythrocyte membrane. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), Saunders, Philadelphia 1997. p.544.</li></ol></div><div id="topicVersionRevision">Topic 7088 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19552676" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Morphological diagnosis of abetalipoproteinemia and the importance of a freshly prepared peripheral smear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654559" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Testing for acanthocytosis A prospective reader-blinded study in movement disorder patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6990496" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hemolytic syndromes and red cell membrane abnormalities in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14164657" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : SPUR-CELL ANEMIA: HEMOLYTIC ANEMIA WITH RED CELLS RESEMBLING ACANTHOCYTES IN ALCOHOLIC CIRRHOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5658871" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Burr cells, hemolytic anemia and cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953338" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hematologic manifestations of liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/710973" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Membrane lipid composition of red blood cells in liver disease: regression of spur cell anaemia after infusion of polyunsaturated phosphatidylcholine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081282" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Spur-Cell Hemolytic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070401" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9565106" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Resolution of spur cell anemia with liver transplantation: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4077979" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11891812" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Severe hypophosphatemia: a rare cause of intravascular hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755560" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Echinocytosis--an unusual manifestation of hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10085435" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ultrastructural changes of erythrocyte membrane skeletons in chorea-acanthocytosis and McLeod syndrome revealed by the quick-freezing and deep-etching method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605368" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl-CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase. A model of spur cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8049442" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abnormal phospholipid metabolism in spur cell anemia: decreased fatty acid incorporation into phosphatidylethanolamine and increased incorporation into acylcarnitine in spur cell anemia erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4827631" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Editorial: "Acanthocytogenesis"--or how the red cell won its spurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4363887" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3064803" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased proteolytic activity of erythrocyte membrane in spur cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15142658" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A basis of the acanthocytosis in inherited and acquired disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24626044" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Abnormal red cell features associated with hereditary neurodegenerative disorders: the neuroacanthocytosis syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33708142" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impaired Cytoskeletal and Membrane Biophysical Properties of Acanthocytes in Hypobetalipoproteinemia - A Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870478" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Echinocytosis induced by haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13463118" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The burr red cell and azotaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13498031" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characterization of the anemia associated with chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4032166" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Erythrocyte lipid alterations in pediatric cholestatic liver disease: spur cell anemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4069170" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/848999" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term management of abetalipoproteinaemia. Possible role for vitamin E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730233" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7378595" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Woronets trait: a new familial erythrocyte anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1257398" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The haematology of hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4182417" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Red-cell shape in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/53639" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Letter: Red-cell changes in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33618863" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35128635" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acanthocytosis in an alectinib-treated patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084939" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute hemolytic anemia with acanthocytosis associated with high-dose misoprostol for medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147873" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : How low is too low: Statin induced hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6348960" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hematologic and immunologic abnormalities in anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4265027" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The haematology of anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12449451" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Abetalipoproteinemia-like lipid profile and acanthocytosis in a young woman with anorexia nervosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2778485" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acanthocytosis associated with myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7584590" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Splenic neoformation following trauma-induced splenectomy--diagnosis and function].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003113" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neuroacanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210889" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neurologic phenotypes associated with acanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760637" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neuroacanthocytosis: new developments in a neglected group of dementing disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37382999" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acanthocytosis: a key feature for the diagnosis of abetalipoproteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26317043" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neuroacanthocytosis: Observations, Theories and Perspectives on the Origin and Significance of Acanthocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742708" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933379" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Abnormal red cell structure and function in neuroacanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016739" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acanthocytosis in Anderson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790728" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New abnormalities in the morphology, cell surface receptors, and electrolyte metabolism of In(Lu) erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6863545" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542027" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542027" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22126643" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : dRTA and hemolytic anemia: first detailed description of SLC4A1 A858D mutation in homozygous state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20799361" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemolytic anemia and distal renal tubular acidosis in two Indian patients homozygous for SLC4A1/AE1 mutation A858D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053187" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Idiopathic thrombocytopenic purpura and hypokalaemic dRTA with compensated haemolysis and striking acanthocytosis in a band 3 (SLC4A1/AE1) A858D homozygote.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207476" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11111093" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lecithin cholesterol acyltransferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5641620" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bile salts and cholesterol in the pathogenesis of target cells in obstructive jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4640953" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5650924" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Abnormalities of erythrocyte stromal lipids in hepatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5774111" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The role of membrane lipids in the survival of red cells in hereditary spherocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3382600" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Alterations in size, shape and osmotic behaviour of red cells after splenectomy: a study of their age dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The life cycle of the erythrocyte after splenectomy and the problems of splenic hemolysis and target cell formation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hematologic changes following splenectomy in man, with particular reference to target cells, hemolytic index, and lysolecithin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052566" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432868" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5704704" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Familial plasma cholesterol ester deficiency. A study of the erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5710162" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The influence of plasma from patients with familial plasma lecithin: cholesterol acyltransferase deficiency on the lipid pattern of erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/746343" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Familial LCAT deficiency. Report of two patients from a Canadian family of Italian and Swedish descent.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
